Hematology Frontier

Florence, Italy — March 30, 2025 – The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) commenced in Florence with a compelling and multifaceted opening ceremony that captured the essence of what the EBMT represents. Far beyond a traditional welcome, the evening unfolded as a rich tapestry of scientific achievement, heartfelt remembrance, and forward-looking vision.

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held from March 30 to April 2, 2025, in Florence, Italy, was not only a scientific…

As the 51st EBMT Annual Meeting concluded in Florence, the closing ceremony offered a moment of reflection, recognition, and renewed purpose. With powerful tributes, standout award presentations, and a forward-looking…

Live biotherapeutic products are rapidly changing the landscape of infection prevention, particularly in immunocompromised patients. Among these, SER-155, a multi-strain oral therapy, has demonstrated compelling clinical results. In a recent trial, the incidence of bloodstream infections (BSIs) dropped sharply in the SER-155 group compared to placebo (10% vs. 42.9%). This finding signals a potential breakthrough in both infection control and microbiome modulation. In this interview, Dr. Doris Ponce discusses the mechanisms behind SER-155, its implications for antimicrobial resistance, and its future applications beyond transplant medicine. Her responses provide an in-depth look at how microbiome science is poised to transform not only prevention but also personalized therapeutic strategies in clinical care.

The 30th Annual Congress of the European Hematology Association (EHA 2025) was held from June 12 to 15 in Milan, Italy, bringing together cutting-edge research and breakthroughs across the global hematology community. Among the highlights was an oral presentation (Abstract S170) by the team of Professor Xiaofan Zhu from the  Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. This study is the first to construct a single-cell atlas of pediatric NRAS-mutated myeloid malignancies, revealing mechanisms of lineage bias and identifying CDK6 as a potential therapeutic target—offering new hope for a mutation historically considered “undruggable.” Oncology Frontier – Hematology Frontier invited Prof. Zhu to discuss the key findings, translational prospects, and major developments in pediatric hematologic malignancies presented at EHA 2025.